Saturday 17 October 2026
Export YI’s income statement to Excel — free account
111, Inc. Sponsored ADR
YI Healthcare Medical Distribution
111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024. In the quarter to March 2026, revenue fell 29.6%, EPS fell 200.0%, free cash flow fell 185.7% and total debt rose 82.5%, each against the same quarter a year earlier.
3.09
0.00
0.00%
Follow YI
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.03 | 0.01 | 0.02 | 0.03 | |
P/FCF ratio |
0.00 | 2.75 | 0.00 | 0.00 | |
P/Operating CF |
(4.31) | 4.95 | 7.35 | (7.40) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.02 | (0.02) | (0.01) | 0.01 | |
EV/EBITDA |
0.00 | 112.75 | 11.29 | 0.00 | |
EV/Operating CF |
(3.16) | (2.25) | (3.55) | 0.91 | |
EV/FCF |
(1.80) | (4.73) | 1.06 | (5.29) | |
Quick Ratio |
0.34 | 0.45 | 0.38 | 0.37 | |
Current Ratio |
1.08 | 1.09 | 1.07 | 1.13 | |
Net Debt/EBITDA |
6.96 | 1,147.50 | 169.59 | (3,684.23) | |
Debt/Assets |
13.32% | 8.53% | 6.85% | 6.86% | |
Debt/Equity |
(0.34) | (0.26) | (0.24) | (0.25) | |
Asset Turnover |
5.16 | 5.16 | 4.75 | 5.34 | |
Operating CF/Net income |
2.48 | (1.79) | (2.96) | 3.07 | |
Capex/Depreciation |
— | (0.37) | — | — | |
Interest Coverage |
(2.54) | (0.03) | (0.32) | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2.99% | 2.84% | 2.58% | 2.61% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(2.10) | (5.12) | (2.83) | (1.81) | |
Graham Number |
19.85 | 16.33 | 14.65 | 14.50 | |
Earnings Yield |
(21.47%) | (39.06%) | (18.46%) | (11.76%) | |
Free Cash Flow Yield |
(36.12%) | 36.37% | (35.09%) | (4.29%) | |
Revenue per Share |
38.93 | 50.58 | 48.39 | 51.56 | |
Operating CF per Share |
(1.51) | 0.52 | 0.62 | (0.96) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.51) | 0.52 | 0.62 | (0.96) | |
Cash per Share |
6.54 | 10.05 | 8.99 | 8.25 | |
Shareholders Equity per Share |
(12.51) | (11.86) | (11.36) | (11.12) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(12.51) | (11.86) | (11.36) | (11.12) | |
Free Cash Flow |
(13.30) | 4.50 | 5.39 | (8.37) | |
Working Capital |
20.81 | 24.48 | 22.72 | 36.89 | |
Capital Expenditures |
— | (0.62) | — | — | |
Net Current Asset Value |
(120.59) | (113.95) | (112.14) | (111.88) | |
EV/EBIT |
0.00 | 112.72 | 11.29 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
32.07 | 46.87 | 50.07 | 46.82 | |
Average Payables |
203.65 | 209.61 | 245.12 | 218.42 | |
Average Inventory |
166.20 | 166.43 | 197.24 | 183.28 | |
Average Assets |
319.93 | 348.28 | 390.21 | 364.76 | |
Average Common Equity |
(101.44) | (96.67) | (94.80) | (91.12) |
Columns are period end dates